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and 6 colorectal cancer) over a mean period of 44.3 treatment
days (Range = 14 to 79 days, Median = 44.3 days, SD = 18.9
days). Overall adherence varied from 85.5% to 100% (Mean =
96.7%, Median = 98.9%, SD = 4.3%). The actual vial opening
intervals among the studied patients varied from 1.6 hours to
18.9 hours (Mean = 12.0 h, Median = 12.0 h, SD = 1.7 h, includ-
ing only days with actual twice daily opening). CONCLUSIONS:
Although the results show in general a high degree of overall
adherence and interval regularity, there were several individuals
who exhibited major discrepancies that may potentially endan-
ger therapeutic goals. The adherence data demonstrated here
form the basis for a prospective, open, controlled, two-armed
observational study investigating the impact of pharmaceutical
care as a multidisciplinary patient-oriented service on adherence
and other relevant clinical, subjective and economic outcome
parameters in a larger patient population.
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OBJECTIVES: Chemotherapy induced nausea and vomiting
(CINV) has a negative impact on HRQoL, but little empirical
data showing relation between failure to control CINV and QoL
aspects other than directly related physical symptoms are avail-
able. The aim is to study dimensions of HRQoL more inﬂuenced
by emesis. METHODS: Prospective, multi-center, observational
study on 325 naïve patients recruited at 8 Spanish Oncology Ser-
vices. Consecutive patients undergoing 1st cycle with moderate
to highly emetogenic chemotherapy and scheduled antiemetic
treatment based on granisetron or ondansetron were enrolled.
After chemotherapy (day 0), daily maximum nausea intensity
and number of vomiting episodes were recorded during 5 more
days in a diary card and then FLIE and EORTC QLQ-C30 were
self-administered. Acute CINV was deﬁned as developed in day
0, and delayed CINV as developed or persisting in days 1–5.
Antiemetic “complete” response was deﬁned as: no emesis and
no/mild nausea. RESULTS: Complete response (CI95%) against
acute and delayed CINV were reported by 78.5% (74.0–83.0%)
and 50.0% (44.5–55.0%) of patients. Response rate was not
related to emetogenicity of chemotherapy (p > 0.05). Physical
Functioning, Dyspnoea, Constipation, Diarrhoea and Financial
Diﬁculties from QLQ-C30 were not sensitive to antiemetic
response against CINV (p > 0.05). Reliability of FLIE improved
when the 4-inverted VAS items were discarded, but discrimina-
tion between antiemetic response groups was maintained. Better
response rates were obtained, in the granisetron arm, in the
dimensions Constipation, Nausea and Vomiting of QLQ-C30
and Vomiting scale of FLIE (p < 0.05). A cost minimization
analysis of CINV global antiemetic treatment reﬂects higher
treatment costs rates in the ondansetron arm. CONCLUSIONS:
Complete CINV prevention agrees with literature but evidence
of association between response rate and emotogenicity of
chemotherapy was not found. Both QLQ-C30 and FLIE were
sensitive to type of response showed by the patients. Reliability
of FLIE Spanish version may be improved.
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OBJECTIVES: As an outcome measure for pharmacoeconomic
studies, quality adjusted life year (QALY) is often used. Though
some indirect measurement tool have been proposed, it is not
widely used in clinical trials in Japan. We started QOL data col-
lection along with a clinical trial on breast cancer treatment
(National Surgical Adjuvant Study of Breast Cancer: N-SAS
BC02). The trial has been supported by Comprehensive Support
Project for Oncology Research and Health Outcomes Research.
The aim of this study is to measure QOL of patients receiving
adjuvant chemotherapy after surgery and investigate the validity
of QOL measurement. METHODS: N-SAS BC02 is a random-
ized controlled trial of AC(adriamycin+cyclophosphamide) and
taxanes. Though main outcome measures are disease-free sur-
vival and overall survival, QOL and economic consequences are
secondary concerns. Quality of life was surveyed 6 times during
one year from 300 samples of participants. We adopted EQ-5D
and visual analogue scale (VAS) as utility measurement. We used
Japanese Tariff for calculate utility score from EQ-5D. We also
used Functional Assessment of Cancer Therapy (FACT) for ref-
erence. RESULTS: Average utility score was 0.806 (SD = 0.161)
from EQ-5D. VAS result showed average of 0.744 (SD = 0.189).
Correlation coefﬁcient of EQ-5D and VAS was 0.47. CON-
CLUSIONS: Many participants have problems in dimensions of
Pain/Discomfort and Anxiety/Depression.
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OBJECTIVES: Existing reports of utility values for second-line
advanced non-small cell lung cancer (NSCLC) vary quite widely
and are not optimal for use in health technology assessments
within the UK. The aim of this study was to elicit UK societal-
based utility values for different tumour response statuses and
different grade 3 and 4 toxicities commonly associated with
NSCLC chemotherapy treatments. METHODS: Toxicities con-
sidered were neutropenia, febrile neutropenia, fatigue, diarrhoea,
nausea and vomiting, rash and hair loss. Each health state
described the symptom burden of disease and impact on differ-
ent levels of functioning (physical, emotional, sexual, and social).
The disutility related to each response status and toxicity was
estimated and combined to give health state values. Existing
health state descriptions of metastatic breast cancer were revised
to make them suitable as descriptions of NSCLC patients receiv-
ing second-line chemotherapy. The existing health states were
used in cognitive debrief interviews with oncologists (n = 5) and
oncology specialist nurses (n = 5). Changes were made as sug-
